HHS Public Access Author manuscript Author Manuscript
Am J Hematol. Author manuscript; available in PMC 2017 October 01. Published in final edited form as: Am J Hematol. 2016 October ; 91(10): E458–E460. doi:10.1002/ajh.24464.
Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation Andrea Havasi1,2, Lauren Stern1,2, Stephen Lo2, Fangui Sun3, and Vaishali Sanchorawala2,4
Author Manuscript
1Department
of Nephrology, Boston University School of Medicine, Boston, MA.
2Amyloidosis
Center, Boston University School of Medicine, Boston, MA.
3Department
of Biostatistics, Boston University School of Public Health, Boston, MA.
4Section
of Hematology-Oncology, Boston University School of Medicine, Boston, MA.
Keywords AL amyloidosis; Proteinuria; eGFR; Staging
To The Editor
Author Manuscript
Palladini et al recently validated simple criteria for baseline staging of renal disease associated with AL amyloidosis [1]. It is imperative to predict the course of progression to end stage renal disease (ESRD) in AL amyloidosis, as development of ESRD markedly increases morbidity and leads to treatment limitations. The proposed staging system based on universally available measurements (i.e. proteinuria and eGFR) sharply discriminated three groups of patients with different probabilities of reaching ESRD. Stage I: eGFR≥50 mL/min/1.73m2 and
Am J Hematol. Author manuscript; available in PMC 2017 October 01. Published in final edited form as: Am J Hematol. 2016 October ; 91(10): E458–E460. doi:10.1002/ajh.24464.
Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation Andrea Havasi1,2, Lauren Stern1,2, Stephen Lo2, Fangui Sun3, and Vaishali Sanchorawala2,4
Author Manuscript
1Department
of Nephrology, Boston University School of Medicine, Boston, MA.
2Amyloidosis
Center, Boston University School of Medicine, Boston, MA.
3Department
of Biostatistics, Boston University School of Public Health, Boston, MA.
4Section
of Hematology-Oncology, Boston University School of Medicine, Boston, MA.
Keywords AL amyloidosis; Proteinuria; eGFR; Staging
To The Editor
Author Manuscript
Palladini et al recently validated simple criteria for baseline staging of renal disease associated with AL amyloidosis [1]. It is imperative to predict the course of progression to end stage renal disease (ESRD) in AL amyloidosis, as development of ESRD markedly increases morbidity and leads to treatment limitations. The proposed staging system based on universally available measurements (i.e. proteinuria and eGFR) sharply discriminated three groups of patients with different probabilities of reaching ESRD. Stage I: eGFR≥50 mL/min/1.73m2 and
